Biotech IPO Funding
Electra Therapeutics Raises $350 Million in Upsized Nasdaq IPO for Immune Disease Trials
Anonymous
Key Points
1
Electra Therapeutics is backed by OrbiMed, according to its IPO disclosure.
2
Electra’s drug candidates target signal regulatory proteins (SIRPs) found on select immune cells, an approach the company says could address immune-mediated diseases without broadly suppressing the body’s defenses. The company wrote, “we believe our approach can do for immune-mediated diseases what precision oncology has done for cancer, transforming the treatment paradigm for patients.”
3
Ipsoprubart is being tested in secondary HLH with the aim of depleting myeloid and T cells that express SIRPs, potentially producing a more targeted immune effect.
4
The IPO was the first biotech offering after Labor Day, and all 21 biotechnology companies that went public in 2026 had a drug in human testing; all 11 that raised at least $300 million had a program in Phase 2 or later.
5
Jefferies, TD Cowen, Evercore ISI and Cantor are serving as joint book-running managers for the offering, which is expected to close on Monday.
Electra Therapeutics raised $350 million in an upsized initial public offering on Thursday, September 17, 2026, pricing 23.3 million shares at $15 each. The clinical-stage biotech firm, MarketScreener reported, began trading on Nasdaq under ticker ETRA the following day, marking strong investor appetite for drug candidates still in human trials.
The company plans to spend most of the proceeds advancing ipsoprubart, an antibody therapy for secondary hemophagocytic lymphohistiocytosis—a rare, life-threatening immune disorder with no approved treatments. MarketScreener noted that Electra became the 21st biotech to go public in 2026 and the 11th to raise over $300 million, reflecting a major rebound in the sector.
A Novel Approach to Immune-Mediated Diseases
Electra targets signal regulatory proteins (SIRPs)—receptors on specific immune cells that activate during disease. The company's strategy depletes harmful myeloid and T cells while preserving broader immune defenses. Electra's lead drug, ipsoprubart, received FDA Breakthrough Therapy Designation and European PRIME status, signaling regulators' confidence in the approach for sHLH, a hyperinflammatory disorder triggered by infections or cancer.
Clinical Performance and Patient Enrollment Timeline
Ipsoprubart showed compelling early results: a Phase 1b trial achieved a 100% overall survival rate at eight weeks and a 100% overall response rate, with 88% complete responses in evaluated patients. MarketScreener reported that the drug is now being tested in a global Phase 2/3 registrational trial, with patient enrollment expected to wrap up in the second half of 2027. Electra estimates roughly 12,600 U.S. patients were diagnosed with sHLH in 2025, growing 11.5% annually.
Strong Capital Allocation and Financial Runway
Electra has allocated $220 million to complete the Phase 2/3 trial and prepare for potential regulatory filings, plus $25 million for a second candidate, ELA822. Combined with $97.7 million in cash reserves from June 2026, the firm now has runway into 2029. CEO Kathy Dong emphasized that sHLH's severity drives immediate patient need, allowing Electra to build commercial capabilities independently without rushing into a Big Pharma partnership.
A Year of Biotech IPO Momentum
Electra's offering caps a strong 2026 for clinical-stage biotechs. All 21 biotech IPOs completed this year had drugs in human testing; all 11 that raised over $300 million had programs in Phase 2 or later. Total sector IPO capital reached $6.8 billion year-to-date, up sharply from $1.3 billion in the same period of 2025. Underwriters Jefferies, TD Cowen, Evercore ISI, and Cantor also hold a 30-day option to buy 3.5 million additional shares worth up to $52.5 million.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
28
Articles
50
Reach
78
A
AnonymousAuthor
